Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study.

Clinical breast cancer - 1 Sept 2026

Önder Tuğba, Ateş Öztürk

Abstract excerpt

BACKGROUND: Chronological age alone poorly reflects physiologic vulnerability in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). We therefore evaluated phenotypic age acceleration (PhenoAgeAccel), a biomarker of biological aging, as a predictor of survival outcomes. METHODS: This...

Read the complete abstract on PubMed

Topics

Humans
Female
Breast Neoplasms
Retrospective Studies
Erb-b2 Receptor Tyrosine Kinases
Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Cyclin-Dependent Kinase 6

Receptors, Progesterone

Protein Kinase Inhibitors

Middle Aged

Receptors, Estrogen

Aged

Prognosis

Adult

Biomarkers, Tumor

Antineoplastic Combined Chemotherapy Protocols

Phenotype

Aged, 80 and over

Source

Identifiers

PMID: 42585849
DOI: 10.1016/j.clbc.2026.07.013

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study.PMID 42585849Read ↗

Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity Read ↗

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read ↗

Ageing phenotypes and behavioural determinants of health on age acceleration: the Cancer Survivors' Trajectories of Ageing Research (C*STAR) study protocol.Semantic proximity Read ↗

Changes in methylation-based aging in women who do and do not develop breast cancerSemantic proximity Read ↗

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.Semantic proximity Read ↗

Methylation-Based Biological Age and Breast Cancer RiskSemantic proximity Read ↗

Using the Cancer Aging and Research Group- Breast Cancer (CARG-BC) predictive model in older adults (OA) with early breast cancer: an external validation studySemantic proximity Read ↗

Decelerated DNA methylation age predicts poor prognosis of breast cancerSemantic proximity Read ↗

Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.Semantic proximity Read ↗

Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancerSemantic proximity Read ↗

DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility.Semantic proximity Read ↗

Engineered Age-Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged MicroenvironmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.